Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. (NASDAQ: GDRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a digital healthcare and medication savings platform. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits covering executive compensation, director arrangements, and key commercial developments.
In its earnings-related Form 8-K filings, GoodRx furnishes press releases that discuss revenue from prescription transactions, subscriptions, and pharma manufacturer solutions, as well as non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income. These documents also describe capital allocation priorities, including investing for growth, debt repayment, share repurchases, and mergers and acquisitions that align with the company’s strategy.
Other 8-K filings provide detail on governance and compensation matters. For example, GoodRx has reported retention bonus agreements for certain executives, including the structure of cash retention bonuses and repayment conditions tied to employment status. It has also disclosed the transition of an executive officer to a non-employee director role, outlining standard non-employee director compensation, committee retainers, and restricted stock unit awards under its non-employee director compensation program and deferred compensation plan.
Through this page, users can access GoodRx’s SEC filings as they are made available via EDGAR. AI-powered summaries on the platform help explain the contents of complex documents, including 10-K and 10-Q reports, by highlighting key themes such as segment performance, prescription transactions trends, subscription and pharma manufacturer solutions growth, and risk factor disclosures. Filings related to insider and director compensation, as well as current reports on material events, are also accessible, giving investors and researchers a structured view of how GoodRx manages its business, governance, and financial reporting obligations.
GoodRx Holdings, Inc. announced that Chief Accounting Officer Romin Nabiey has submitted his resignation, effective April 3, 2026, to pursue other opportunities. He will remain with the company through June 8, 2026 to help transition his responsibilities. The company stated that his resignation is not due to any disagreement regarding its operations, policies, or practices, and expressed appreciation for his years of service.
GoodRx Holdings Inc filing an amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares (0%) of Common Stock as shown in the amendment dated 03/13/2026. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
GoodRx Holdings, Inc. has changed its independent auditor. The Audit and Risk Committee approved the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and dismissed PricewaterhouseCoopers LLP from this role.
PWC’s audit reports on the 2025 and 2024 consolidated financial statements contained no adverse opinions, disclaimers, or qualifications. The company reports no disagreements or reportable events with PwC through March 14, 2026, and states it did not consult KPMG on accounting or auditing matters before this appointment.
GoodRx Holdings, Inc. director Agnes Rey-Giraud exercised stock options to acquire 192,185 shares of Class A common stock at $0.47 per share. On the same date, she made bona fide gifts totaling 150,438 shares, including 75,219 shares transferred to a family trust for which she is the sole trustee and beneficiary. Following these transactions, she continues to hold a substantial direct position in GoodRx stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity transactions involving restricted stock units and Class A common stock. On March 8, 2026, restricted stock units were converted into a total of 10,201 and 2,233 shares of Class A common stock at a price of $0.00 per share through derivative exercises.
In connection with these conversions, Class A shares were also disposed of under transaction code F to cover tax obligations, with 4,201 shares and 920 shares withheld at a price of $2.28 per share as tax-withholding dispositions. After these transactions, Nabiey directly owned 183,061 shares of Class A common stock.
Footnotes explain that each restricted stock unit represents a contingent right to receive one share of Class A common stock. One award began vesting December 8, 2022 with quarterly installments over 15 quarters, and another will begin vesting June 8, 2024 on a similar quarterly schedule.
GoodRx Holdings, Inc. reported a new executive compensation decision. On March 3, 2026, the Board of Directors, following a recommendation from its Compensation Committee, approved a discretionary cash bonus of $72,918 to Chief Accounting Officer Romin Nabiey for his performance during 2025.
McGinnis Christopher A reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. reported that executive Christopher A. McGinnis received a grant of 443,852 restricted stock units on Class A common stock. Each unit represents a right to receive one share at no purchase price.
The restricted stock units vest in 12 equal quarterly installments, with the first vesting on April 15, 2026, and are subject to continued service through each vesting date. Following this award, McGinnis directly holds 126,321 shares of Class A common stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported an equity compensation grant. On March 3, 2026, Nabiey acquired 108,189 restricted stock units, each representing a contingent right to receive one share of Class A common stock. These RSUs will vest in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to continued service. Following this report, Nabiey held 175,748 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported that director and officer Wendy Lynn Barnes acquired 1,331,557 restricted stock units on March 3, 2026 as an equity award. Each restricted stock unit represents a right to receive one share of Class A common stock.
The award will vest ratably in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to her continued service through each vesting date. Following this award, she also held 427,993 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported that board member Dipanjan Deb resigned from its Board of Directors, effective February 26, 2026. The company states that Mr. Deb’s decision to step down was not due to any disagreement with GoodRx or its management regarding operations, policies, or practices.